TCM Life Science Inc. — SEC Form D Filing

TCM Life Science Inc. filed an SEC Form D on October 26, 2026, reporting $17K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 26, 2026
Amount reported
$17K
Round stage
Pre-seed because the $16,666 raise represents initial formation capital for foundational administrative and preliminary laboratory setup.
Industry
Biotechnology
Website
https://www.tcmlifescience.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Pharmaceutical developers face significant technical challenges in standardizing and validating bioactive compounds derived from traditional natural sources for modern clinical applications.

Solution

TCM Life Science develops a biotechnology platform focused on isolating, standardizing, and advancing novel therapeutic compounds for drug discovery.

Why now

Advancements in mass spectrometry and genomic screening now enable precise characterization of complex biological formulations that were historically difficult to validate.

Source: SEC EDGAR Form D filing